DRUG(DRUG)
DRUG
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E | FY2028E | FY2029E | FY2030E |
|---|---|---|---|---|---|
| Revenue Avg | — | $34M | — | — | — |
| Low | — | $34M | — | — | — |
| High | — | $34M | — | — | — |
| EBITDA Avg | — | — | — | — | — |
| Low | — | — | — | — | — |
| High | — | — | — | — | — |
| EBIT Avg | — | — | — | — | — |
| Low | — | — | — | — | — |
| High | — | — | — | — | — |
| Net Income Avg | $-46M | $-85M | $-90M | $-112M | $-62M |
| Low | $-55M | $-88M | $-125M | $-112M | $-62M |
| High | $-37M | $-83M | $-55M | $-112M | $-62M |
| EPS Avg | $-6.59 | $-12.41 | $-14.61 | $-16.24 | $-9.00 |
| Low | $-7.97 | $-12.78 | $-18.21 | $-16.24 | $-9.00 |
| High | $-5.32 | $-12.03 | $-8.05 | $-16.24 | $-9.00 |
| Analysts (Rev / EPS) | — / 5 | 7 / 5 | — / 6 | — / 3 | — / 2 |
| Metric | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 |
|---|---|---|---|---|---|
| Revenue Avg | — | — | — | — | — |
| Low | — | — | — | — | — |
| High | — | — | — | — | — |
| EBITDA Avg | — | — | — | — | — |
| Low | — | — | — | — | — |
| High | — | — | — | — | — |
| EBIT Avg | — | — | — | — | — |
| Low | — | — | — | — | — |
| High | — | — | — | — | — |
| Net Income Avg | $-24M | $-26M | $-31M | $-31M | $-35M |
| Low | $-30M | $-26M | $-31M | $-31M | $-35M |
| High | $-17M | $-26M | $-31M | $-31M | $-35M |
| EPS Avg | $-2.46 | $-2.73 | $-3.18 | $-3.23 | $-3.61 |
| Low | $-3.12 | $-2.73 | $-3.18 | $-3.23 | $-3.61 |
| High | $-1.80 | $-2.73 | $-3.18 | $-3.23 | $-3.61 |
| Analysts (Rev / EPS) | — / 4 | — / 2 | — / 2 | — / 1 | — / 1 |